Clinical Trial Update: Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms [Phase 2]

View source ↗

Summary

This entry updates a Phase 2 clinical trial evaluating OTX-601 for reducing post-traumatic stress disorder symptoms, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• OTX-601

Snippet

Sponsor: Oui Therapeutics, Inc. | Conditions: PTSD, Post Traumatic Stress Disorder | Phase 2 | Status: RECRUITING